Skip to contentpdufa.bio

Nenocorilant

Page updated ·next FDA decision on the calendar ·Data as of Nov 19, 2026 12:24 AM ET

Nenocorilant is a Corcept Therapeutics Inc program in solid tumors. Its next catalyst is a Readout in Q4 2027.

CORT catalyst hub

All upcoming FDA decision dates on the 2026 PDUFA calendar

About this program

Indication under review: Solid tumors. Sponsor: Corcept Therapeutics Inc (CORT). We track 1 catalyst event for this program: 1 upcoming and 0 in the record. A PDUFA date is the FDA's target date to complete review of a marketing application; a readout is the sponsor's expected date for clinical trial results. What a PDUFA date is · why we do not compare trial results across drugs.

Catalyst history

Readout · Q4 2027CORT

Questions

When is Nenocorilant's next FDA decision or readout?

The next tracked catalyst for Nenocorilant is a Readout in Q4 2027.

What happened at Nenocorilant's most recent FDA decision?

No FDA decision for Nenocorilant is in our archive yet.

What is Nenocorilant used for?

In our records Nenocorilant is under review or in development for Solid tumors.

Who makes Nenocorilant?

Corcept Therapeutics Inc (CORT).

Where does this data come from?

FDA announcements, sponsor press releases and SEC filings. Each FDA decision links its own page, which names its source or says plainly that it has none.